Stock ONVO ORGANOVO HOLDINGS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Organovo Holdings, Inc.

Equities

ONVO

US68620A2033

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 01:30:00 09/05/2024 am IST 		5-day change 1st Jan Change
0.96 USD +5.49% Intraday chart for Organovo Holdings, Inc. +3.10% -13.51%
15/04 Organovo's fatty liver disease drug meets main goal in mid-stage study RE
15/04 Organovo Holdings, Inc. Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo CI

Valuation

Fiscal Period: March 2019 2023 2024 2025 2026
Capitalization 1 118.5 19.08 10.94 - -
Enterprise Value (EV) 1 118.5 19.08 10.94 10.94 10.94
P/E ratio -4.31 x -1.11 x -0.55 x -0.68 x -0.7 x
Yield - - - - -
Capitalization / Revenue 38.3 x - 146 x 24.6 x 20.5 x
EV / Revenue 38.3 x - 146 x 24.6 x 20.5 x
EV / EBITDA - - - - -
EV / FCF - - - - -
FCF Yield - - - - -
Price to Book - - - - -
Nbr of stocks (in thousands) 5,975 8,715 11,391 - -
Reference price 2 19.84 2.190 0.9600 0.9600 0.9600
Announcement Date 22/05/19 14/07/23 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2019 2023 2024 2025 2026
Net sales 1 3.091 - 0.075 0.444 0.533
EBITDA - - - - -
EBIT -27.27 - - - -
Operating Margin -882.37% - - - -
Earnings before Tax (EBT) -26.63 - - - -
Net income -26.64 -17.26 - - -
Net margin -861.7% - - - -
EPS 2 -4.600 -1.980 -1.740 -1.410 -1.370
Free Cash Flow - - - - -
FCF margin - - - - -
FCF Conversion (EBITDA) - - - - -
FCF Conversion (Net income) - - - - -
Dividend per Share - - - - -
Announcement Date 22/05/19 14/07/23 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: March 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2 2025 Q3 2025 Q4
Net sales 1 - - 0.005 0.075 0.1 0.1 0.12 0.124
EBITDA - - - - - - - -
EBIT - -4.115 -3.68 - - - - -
Operating Margin - - -73,600% - - - - -
Earnings before Tax (EBT) - - - - - - - -
Net income -4.028 -3.994 -3.604 - - - - -
Net margin - - -72,080% - - - - -
EPS 2 -0.4600 -0.4600 -0.4000 -0.4200 -0.3800 -0.3600 -0.3600 -0.3100
Dividend per Share - - - - - - - -
Announcement Date 10/08/23 09/11/23 08/02/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: March 2019 2023 2024 2025 2026
Net Debt - - - - -
Net Cash position - - - - -
Leverage (Debt/EBITDA) - - - - -
Free Cash Flow - - - - -
ROE (net income / shareholders' equity) - - - - -
ROA (Net income/ Total Assets) - - - - -
Assets - - - - -
Book Value Per Share - - - - -
Cash Flow per Share - - - - -
Capex - - - - -
Capex / Sales - - - - -
Announcement Date 22/05/19 14/07/23 - - -
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
ORGANOVO HOLDINGS, INC. Stock Organovo Holdings, Inc.
-13.51% 10.94M
MODERNA, INC. Stock Moderna, Inc.
+22.56% 46.71B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-1.51% 41.52B
LONZA GROUP AG Stock Lonza Group AG
+48.83% 41.8B
CELLTRION, INC. Stock Celltrion, Inc.
-3.42% 29.55B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+10.13% 25.78B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-20.44% 19.26B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+26.45% 11.98B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-0.14% 12.14B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-0.47% 12.08B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. ONVO Stock
  4. Financials Organovo Holdings, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW